In a significant healthcare policy shift, the National Health Service (NHS) has authorised free Wegovy weight-loss injections for approximately 1.2 million individuals across the United Kingdom who meet specific health criteria. This expansion targets those classified as overweight rather than solely obese, provided they have a history of cardiovascular issues such as heart attacks, strokes, or circulation problems in their legs.
New Eligibility Criteria for Wegovy Access
Previously, Wegovy was only available on NHS prescription for individuals with a Body Mass Index (BMI) of 35 or higher, categorising them as obese. Under updated guidelines from the National Institute for Health and Care Excellence (NICE), the threshold has been reduced to a BMI of 27 or above, now including those deemed overweight. This change broadens access to the drug, which is set to roll out from this summer.
How Wegovy Works and Its Benefits
Wegovy, a GLP-1 medication similar to Mounjaro and Ozempic, contains semaglutide. This active ingredient helps increase feelings of fullness and reduce appetite, aiding in weight loss. Clinical trials indicate that, on average, users lose around 21 percent of their body weight after 72 weeks of treatment. Additionally, Wegovy promotes insulin release and lowers blood sugar, offering dual benefits for metabolic health.
Helen Knight from NICE emphasised the importance of this decision, stating, "We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke."
Expert Insights and Broader Implications
Professor Naveed Sattar, a specialist in cardiometabolic medicine at the University of Glasgow, welcomed the move, highlighting its potential impact. "This is very good news and stems directly from high quality trial evidence. We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss – which in turn lowers the risk of many weight‑related conditions," he explained.
Professor Sattar added that addressing weight directly is crucial for optimal patient outcomes, especially since many with cardiovascular disease struggle with excess weight. He noted that this guidance represents a major turning point in combating obesity and expressed hope for more affordable treatments in the future.
Administration and Considerations
Wegovy is administered as a weekly injection, with dosages gradually increased as the body adjusts. It will be offered alongside existing cardiovascular medications, such as statins, to enhance protection against further health incidents. However, experts caution that users should maintain an effective exercise regime to prevent excessive muscle mass loss during weight reduction.
Research published in The Lancet suggests that semaglutide injections may reduce heart attack and stroke risks regardless of weight loss, though lifestyle factors remain important. Common side effects listed by the drug's official website include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Headache
- Tiredness
- Upset stomach
- Dizziness
- Feeling bloated
- Belching
- Low blood sugar in people with type 2 diabetes
- Gas
- Stomach flu
- Heartburn
- Runny nose or sore throat
This initiative underscores the NHS's commitment to preventive care, potentially transforming lives by reducing the burden of cardiovascular diseases through accessible, evidence-based treatments.
